Protease inhibition causes some manifestations of aging and Alzheimer's disease in rodent and primate brain.
Ivy
G O
GO
Division of Life Sciences, University of Toronto, Scarborough, Ontario, Canada.
D000375:Aging / Q000378:metabolism*; D000544:Alzheimer Disease / Q000201:enzymology* / Q000378:metabolism; D000818:Animals; D001921:Brain / Q000201:enzymology / Q000378:metabolism; D004286:Dolichols / Q000378:metabolism; D010450:Endopeptidases / Q000378:metabolism*; D006801:Humans; D007158:Immunologic Techniques; D007382:Intermediate Filaments / Q000378:metabolism; D007930:Leucine / Q000031:analogs & derivatives / Q000494:pharmacology; D007976:Leupeptins / Q000494:pharmacology; D008062:Lipofuscin / Q000378:metabolism; D008252:Macaca fascicularis; D008297:Male; D011480:Protease Inhibitors / Q000494:pharmacology*; D051381:Rats; D011916:Rats, Inbred F344; D017207:Rats, Sprague-Dawley; D014452:Ubiquitins / Q000378:metabolism
D004286:Dolichols; D007976:Leupeptins; D008062:Lipofuscin; D011480:Protease Inhibitors; D014452:Ubiquitins; C032425:N-(N-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine; D010450:Endopeptidases; D007930:Leucine; C032854:leupeptin